EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer

Yangyang Han iD, Mengqi Zhang, Mannizire Rehemujiang, Xintong Li, Yimin Liu, Niuniu Zhang, Meng Sun, Yunbo Zhang, Ayshamgul Hasim, Mengjia Li iD

International Journal of Molecular Sciences · 05.07.2026 · 27 (13) · 6040

DOI: 10.3390/ijms27136040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.07.2026. Verfasst von Yangyang Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830017, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Protein Serine-Threonine Kinases, Computational Biology. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Open Research Fund Project of Key Laboratory of High Incidence Disease Research in Xinjiang,Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unc-51-like kinase 3 (ULK3) is a key member of the ULK serine/threonine kinase family. Aberrant ULK3 expression has been increasingly linked to tumorigenesis and malignant progression in multiple cancer types. However, the precise role of ULK3 in tumor initiation and progression remains incompletely understood. Leveraging integrated multi-omics data from The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) project, and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), we systematically characterized the expression of ULK3 at both the transcript and protein levels across 33 cancer types. We also evaluated genomic alterations, prognostic significance, alternative splicing, pathway enrichment, tumor stemness, immune infiltration, and immunotherapy-related biomarkers. In parallel, we investigated the function of ULK3 in prostate cancer PC-3 cells using cellular localization analysis, wound-healing assays, and MTT assays. We further applied Connectivity Map (CMap) screening and molecular docking to identify candidate ULK3 activators. ULK3 was significantly upregulated in 13 cancer types, including Bladder Urothelial Carcinoma, Breast Invasive Carcinoma, and Lung Adenocarcinoma. In contrast, ULK3 was downregulated in Cholangiocarcinoma and Head and Neck Squamous Cell Carcinoma. High ULK3 expression was associated with poor overall survival in Adrenocortical Carcinoma, Kidney Renal Clear Cell Carcinoma, and Skin Cutaneous Melanoma. Copy number amplification contributed to ULK3 overexpression. A recurrent A206V missense mutation was detected in the protein kinase (Pkinase) domain. Genes co-expressed with ULK3 were enriched in RNA splicing, methylation, oxidative phosphorylation, and energy metabolism. ULK3 expression showed positive correlations with tumor stemness indices and m1A/m5C/m6A RNA modification regulators. From an immunological perspective, high ULK3 expression was associated with lower Immune Score, increased M2 macrophage infiltration, and co-expression of PD-L1, CTLA4, and LAG3 in most cancers. ULK3 expression was also correlated with Tumor Mutational Burden in Kidney Renal Clear Cell Carcinoma and Rectum Adenocarcinoma. In addition, ULK3 expression was associated with Microsatellite Instability in Brain Lower Grade Glioma, Lung Adenocarcinoma, and Uterine Corpus Endometrial Carcinoma. ULK3 overexpression promoted proliferation and migration in PC-3 cells. Cephaeline was screened as a putative ULK3 activator. Overall, ULK3 expression and amplification were associated with poor clinical outcomes, tumor stemness, immunosuppression, and RNA dysregulation. These findings highlight the potential value of ULK3 as a pan-cancer diagnostic and prognostic biomarker and as a predictor of immunotherapy response, particularly in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProtein Serine-Threonine KinasesComputational BiologyHumansMaleGene Expression Regulation, NeoplasticDisease ProgressionBiomarkers, TumorCell Line, TumorPrognosis

Stichwörter der Autor:innen

ULK3immunitypan-cancerprognostic biomarkersprostate cancer

Substanzen

Protein Serine-Threonine KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830017, China.
  • Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830017, China.
  • Key Laboratory of High Incidence Disease Research in Xingjiang, Xinjiang Medical University, Ministry of Education, Urumqi 830017, China.
  • Department of Basic Medicine, Xinjiang Medical University, Urumqi 830017, China.

ORCID-Profile: Yangyang Han, Mengjia Li

Förderung

  • National Natural Science Foundation of China
  • Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases
  • Open Research Fund Project of Key Laboratory of High Incidence Disease Research in Xinjiang,Ministry of Education
  • Open Research Fund Project of Key Laboratory of High Incidence Disease Research in Xinjiang, Ministry of Education

Zitieren

APA

Han, Y., Zhang, M., Rehemujiang, M., Li, X., Liu, Y., Zhang, N., Sun, M., Zhang, Y., Hasim, A., & Li, M. (2026). The Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer. International Journal of Molecular Sciences, 27(13), 6040. https://doi.org/10.3390/ijms27136040

Vancouver

Han Y, Zhang M, Rehemujiang M, Li X, Liu Y, Zhang N, et al. The Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer. International Journal of Molecular Sciences. 2026;27(13):6040. doi:10.3390/ijms27136040

BibTeX
@article{Han2026,
  author = {Han, Yangyang and Zhang, Mengqi and Rehemujiang, Mannizire and Li, Xintong and Liu, Yimin and Zhang, Niuniu and Sun, Meng and Zhang, Yunbo and Hasim, Ayshamgul and Li, Mengjia},
  title = {The Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {13},
  pages = {6040},
  doi = {10.3390/ijms27136040}
}
Kostenlos starten →